Metadherin overexpression in perihilar cholangiocarcinoma is associated with lymph node metastasis and poor prognosis

Zhu,Yan‑Zhi; Zhou,Ke; Ruan,Lin‑Lin; Sun,Fu; Wang,Gen; Li,Wen‑Fang

doi:10.3892/ol.2019.10141

Metadherin overexpression in perihilar cholangiocarcinoma is associated with lymph node metastasis and poor prognosis

Authors:
- Yan‑Zhi Zhu
- Ke Zhou
- Lin‑Lin Ruan
- Fu Sun
- Gen Wang
- Wen‑Fang Li
View Affiliations

Affiliations: Department of General Surgery, Taihe Hospital Affiliated with Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Pathology, Taihe Hospital Affiliated with Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Pathology, First Affiliated Hospital of Xi'an Medical University, Xi'an, Shanxi 710000, P.R. China
Published online on: March 12, 2019 https://doi.org/10.3892/ol.2019.10141
Pages: 4514-4520
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metadherin (MTDH) is a protein that is also named astrocyte elevated gene‑1, and is highly expressed in a number of different tumor tissues. Although the expression of MTDH is associated with tumor invasion and recurrence, the expression of this protein in perihilar cholangiocarcinoma (PCCA) and its clinical use have not yet been investigated. In the present study, the expression of MTDH in patients with PCCA was investigated in order to determine its clinicopathological use. An immunohistochemical method was used to detect MTDH expression and the epithelial‑mesenchymal transition markers E‑cadherin and vimentin in 66 cases of PCCA. In addition to the expression of MTDH, the clinical and pathological data and the postoperative outcomes were analyzed. The MTDH positive expression rate was 48.5% (32/66) in PCCA. A significantly higher MTDH expression level was identified in the poor tumor differentiation group compared with the well differentiation group (P=0.007). In the positive lymph node metastasis group, a significantly higher MTDH expression level was revealed compared with the negative lymph node metastasis group (P=0.023). No association was noted with regard to the expression of MTDH and the variables age, sex, tumor diameter, tumor grade and tumor classification stage. Positive MTDH expression was significantly associated with high vimentin expression (P=0.037) compared with negative vimentin expression and inversely associated with positive E‑cadherin expression compared with negative E‑cadherin expression (P=0.030). Survival analysis suggested that the high MTDH expression group was associated with a worse overall survival (OS) rate and recurrence free survival (RFS) rate compared with the low MTDH expression group (P<0.001 and P=0.01, respectively). Cox regression analysis indicated that the Tumor‑Node‑Metastasis, surgery margin and high MTDH expression were independent OS and RFS factors for PCCA. MTDH expression may serve an important function in PCCA tumor growth and metastasis. Targeting MTDH may have important therapeutic applications for patients with PCCA.

View Figures

View References

1	Patel T: Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 3:33–42. 2006. View Article : Google Scholar : PubMed/NCBI
2	Zhao W, Zhang B, Guo X, Zhang X, Hu J, Hu X and Lu Y: Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma. Cancer Biomark. 14:197–202. 2014. View Article : Google Scholar : PubMed/NCBI
3	Chauhan A, House MG, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ, Schmidt CM, Ball CG and Lillemoe KD: Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB (Oxford). 13:139–147. 2011. View Article : Google Scholar : PubMed/NCBI
4	Cheng Y, Chen Y and Chen H: Application of portal parenchyma-enterostomy after high hilar resection for Bismuth type IV hilar cholangiocarcinoma. Am Surg. 76:182–187. 2010.PubMed/NCBI
5	Liu Y, Su ZW, Li G, Yu C, Ren S, Huang D, Fan S, Tian Y, Zhang X and Qiu Y: Increased expression of metadherin protein predicts worse disease-free and overall survival in laryngeal squamous cell carcinoma. Int J Cancer. 133:671–679. 2013. View Article : Google Scholar : PubMed/NCBI
6	Hu G, Wei Y and Kang Y: The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res. 15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
7	Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ and Fisher PB: Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 21:3592–3602. 2002. View Article : Google Scholar : PubMed/NCBI
8	Brown DM and Ruoslahti E: Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell. 5:365–374. 2004. View Article : Google Scholar : PubMed/NCBI
9	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
10	Sarkar D and Fisher PB: AEG-1/MTDH/LYRIC: Clinical significance. Adv Cancer Res. 120:39–74. 2013. View Article : Google Scholar : PubMed/NCBI
11	Yu C, Liu Y, Tan H, Li G, Su Z, Ren S, Zhu G, Tian Y, Qiu Y and Zhang X: Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signalling pathway-mediated epithelial-mesenchvmal transition. Cancer Lett. 343:258–267. 2014. View Article : Google Scholar : PubMed/NCBI
12	Hu G, Chong RA, Yanu Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG and Kang Y: MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 15:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
13	Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, Ding ZB, Shi GM, Ke AW, Yang XR, et al: Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 17:7294–7302. 2011. View Article : Google Scholar : PubMed/NCBI
14	Madhusudhan KS, Gamanagatti S and Gupta AK: Imaging and interventions in hilar cholangiocarcinoma: A review. World J Radiol. 7:28–44. 2015. View Article : Google Scholar : PubMed/NCBI
15	Poruk KE, Pawlik TM and Weiss MJ: Perioperative management of hilar cholangiocarcinoma. J Gastrointest Sura. 19:1889–1899. 2015. View Article : Google Scholar
16	Amin MB: AJCC Cancer Staging Manual. 8th. American Joint Committee on Cancer. Springer; New York, NY: 2016
17	Wang F, Liu Y and Zhang H: Loss of MTSS1 expression is an independent prognostic factor for hilar cholangiocarcinoma. Pathol Oncol Res. 19:815–820. 2013. View Article : Google Scholar : PubMed/NCBI
18	Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B and Hong ST: Epidemiology of cholangiocarcinoma: An update focusing on risk factors. Cancer Sci. 101:579–585. 2010. View Article : Google Scholar : PubMed/NCBI
19	Endo I, House MG, Klimstra DS, Gönen M, D'Angelica M, Dematteo RP, Fong Y, Blumgart LH and Jarnagin WR: Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 15:2104–2112. 2008. View Article : Google Scholar : PubMed/NCBI
20	Welling TH, Feng M, Wan S, Hwang SY, Volk ML, Lawrence TS, Zalupski MM and Sonnenday CJ: Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl. 20:81–88. 2014. View Article : Google Scholar : PubMed/NCBI
21	Otani K, Chijiiwa K, Kai M, Ohuchida J, Nagano M, Tsuchiya K and Kondo K: Outcome of surgical treatment of hilar cholangiocarcinoma. J Gastrointest Surg. 12:1033–1040. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liu G, Huang X, Cui X, Zhang J, Wei L, Ni R and Lu C: High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol. 30:5372013. View Article : Google Scholar : PubMed/NCBI
23	Huang W, Yang L, Liang S, Liu D, Chen X, Ma Z, Zhai S, Li P and Wang X: AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers. Dig Dis Sci. 58:2873–2880. 2013. View Article : Google Scholar : PubMed/NCBI
24	Yao Y, Gu X, Liu H, Wu G, Yuan D, Yang X and Song Y: Metadherin regulates proliferation and metastasis via actin cytoskeletal remodelling in non-small cell lung cancer. Br J Cancer. 111:355–364. 2014. View Article : Google Scholar : PubMed/NCBI
25	Emdad L, Darker D, Su ZZ, Randolph A, Boukerche H, Valerie K and Fisher PB: Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: Implications for tumor progression and metastasis. Cancer Res. 66:1509–1516. 2006. View Article : Google Scholar : PubMed/NCBI
26	Nikpour M, Emadi-Baygi M, Fischer U, Niegisch G, Schulz WA and Nikpour P: MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer. Urol Oncol. 32:670–677. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yu C, Liu Y, Tan H, Li G, Su Z, Ren S, Zhu G, Tian Y, Qiu Y and Zhang X: Metadherin regulates metastasis of squamous cell carcinoma of the head and neck via AKT signaling pathway-mediated epithelial-mesenchymal transition. Cancer Lett. 343:258–267. 2014. View Article : Google Scholar : PubMed/NCBI
28	Hui AB, Bruce JP, Alajez NM, Shi W, Yue S, Perez-Ordonez B, Xu W, O'Sullivan B, Waldron J, Cummings B, et al: Significance of dysregulated metadherin and microRNA-375 in head and neck cancer. Clin Cancer Res. 17:7539–7550. 2011. View Article : Google Scholar : PubMed/NCBI
29	Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS and Marrero JA: Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 21:793–799. 2012. View Article : Google Scholar : PubMed/NCBI
30	Luo Z, Hu X, Xiong H, Qiu H, Yuan X, Zhu F, Wang Y and Zou Y: A polysaccharide from Huaier induced apoptosis in MCF-7 breast cancer cells via down-regulation of MTDH protein. Carbohydr Polym. 151:1027–1033. 2016. View Article : Google Scholar : PubMed/NCBI
31	Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 365:671–679. 2005. View Article : Google Scholar : PubMed/NCBI
32	Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W and Yu SC: Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford). 16:366–372. 2014. View Article : Google Scholar : PubMed/NCBI
33	Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P and Singal AG: Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 12:870–877. 2014. View Article : Google Scholar : PubMed/NCBI
34	Moore RF, Sholl AB, Kidd L, Al-Qurayshi Z, Tsumagari K, Emejulu OM, Kholmatov R, Friedlander P, Abd Elmageed ZY and Kandil E: Metadherin expression is associated with extrathyroidal extension in papillary thyroid cancer patients. Ann Surg Oncol. 23:2883–2888. 2016. View Article : Google Scholar : PubMed/NCBI
35	Yu J, Wang JG, Zhang L, Yang HP, Wang L, Ding D, Chen Q, Yang WL, Ren KH, Zhou DM, et al: MicroRNA-320a inhibits breast cancer metastasis by targeting metadherin. Oncotarget. 7:38612–38625. 2016.PubMed/NCBI
36	Liu Y, Kong X, Li X, Li B and Yang Q: Knockdown of metadherin inhibits angiogenesis in breast cancer. Int J Oncol. 46:2459–2466. 2015. View Article : Google Scholar : PubMed/NCBI
37	Yu C, Chen K, Zheng H, Guo X, Jia W, Li M, Zeng M, Li J and Song L: Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 30:894–901. 2009. View Article : Google Scholar : PubMed/NCBI
38	Wei YB, Guo Q, Gao YL, Yan B, Wang Z, Yang JR and Liu W: Repression of metadherin inhibits biological behavior of prostate cancer cells and enhances their sensitivity to cisplatin. Mol Med Rep. 12:226–232. 2015. View Article : Google Scholar : PubMed/NCBI
39	Huang S, Wu B, Li D, Zhou W, Deng G, Zhang K and Li Y: Knockdown of astrocyte elevated gene-1 inhibits tumor growth and modifies microRNAs expression profiles in human colorectal cancer cells. Biochem Biophys Res Commun. 444:338–345. 2014. View Article : Google Scholar : PubMed/NCBI
40	Zhou CX, Wang CL, Yu AL, Wang QY, Zhan MN, Tang J, Gong XF, Yin QQ, He M, He JR, et al: MiR-630 suppresses breast cancer progression by targeting metadherin. Oncotarget. 7:1288–1299. 2016.PubMed/NCBI